DeepMed Research

Amprenavir

Generic Name: Amprenavir

Drug Type: Small Molecule

Chemical Formula: C_₂₅H_₃₅N_₃O_₆S

CAS Number: 161814-49-9

Unique Ingredient Identifier: 5S0W860XNR

Background: Amprenavir is a protease inhibitor used to treat HIV infection.

Indication: 用于高效抗逆转录病毒疗法（HAART）的组成药物。

Clinical Trials

A Study on Amprenavir in Combination With Other Anti-HIV Drugs in HIV-Positive Patients

Phase 2

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2021-10-29

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 475

Registration Number: NCT00000912

Locations: 🇺🇸
USC Univ Hosp & Ambulatory Hlth Care Ctr / USC Med Ctr, Los Angeles, California, United States
🇺🇸
Emory Univ, Atlanta, Georgia, United States
🇺🇸
UCLA CARE Ctr, Los Angeles, California, United States

and more 42 locations

An Open-Label Study to Evaluate the Efficacy and Safety of Amprenavir (141W94) and Abacavir Combination Therapy in Protease Inhibitor Experienced Subjects With HIV-1 Infection Who Are Failing Their Current Antiretroviral Treatment Regimen

Not Applicable

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2005-06-24

Lead Sponsor: Glaxo Wellcome

Registration Number: NCT00002205

Locations: 🇺🇸
Glaxo Wellcome Inc, Research Triangle Park, North Carolina, United States

A Study of 141W94 Used Alone or in Combination With Zidovudine Plus 3TC in HIV-Infected Patients

Phase 2

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2021-11-04

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 94

Registration Number: NCT00001085

Locations: 🇺🇸
The Ponce de Leon Ctr. CRS, Atlanta, Georgia, United States
🇺🇸
Rush Univ. Med. Ctr. ACTG CRS, Chicago, Illinois, United States
🇺🇸
Cook County Hosp. CORE Ctr., Chicago, Illinois, United States

and more 12 locations

Evaluation of Specific Infection-Fighting Cells For Prediction of Immune Response to Anti-HIV and Immune-Boosting Medication

Not Applicable

Withdrawn

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2015-03-09

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Registration Number: NCT00006578

Locations: 🇺🇸
Univ of Colorado Health Sciences Ctr, Denver, Colorado, United States
🇺🇸
Univ of Miami School of Medicine, Miami, Florida, United States
🇺🇸
Northwestern Univ Med School, Chicago, Illinois, United States

and more 2 locations

A Study to See If Taking One or Two Extra Drugs Can Lower HIV Levels in Patients Who Have Failed Their Anti-HIV Drug Treatment

Phase 2

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2021-11-01

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 42

Registration Number: NCT00006152

Locations: 🇺🇸
Beth Israel Deaconess - West Campus, Boston, Massachusetts, United States
🇺🇸
Univ of Texas Galveston, Galveston, Texas, United States
🇺🇸
Univ of Southern California / LA County USC Med Ctr, Los Angeles, California, United States

and more 10 locations

A Study to Evaluate Various Combinations of Anti-HIV Medications to Treat Early HIV Infection

Not Applicable

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2012-06-07

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 900

Registration Number: NCT00000919

Locations: 🇺🇸
Univ of Southern California / LA County USC Med Ctr, Los Angeles, California, United States
🇺🇸
Marin County Specialty Clinic, San Rafael, California, United States
🇺🇸
Emory Hemo Comp Evaluation Clinic / East TN Comp Hemo Ctr, Atlanta, Georgia, United States

and more 77 locations

A Study of the Effects of Amprenavir, a Protease Inhibitor, on Carbohydrate and Fat Metabolism in HIV-Infected Patients

Phase 3

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2005-06-24

Lead Sponsor: Glaxo Wellcome

Registration Number: NCT00002245

Locations: 🇺🇸
LAC / USC Med Ctr / Infectious Diseases, Los Angeles, California, United States

A Study of Amprenavir in Patients With Protease Inhibitor-Related Complications

Not Applicable

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2005-06-24

Lead Sponsor: Glaxo Wellcome

Registration Number: NCT00002417

Locations: 🇺🇸
Glaxo Wellcome Inc, Research Triangle Park, North Carolina, United States

Effectiveness and Safety of Epivir/Ziagen/Zerit (3TC/ABC/d4T) Versus Epivir/Ziagen/Sustiva (3TC/ABC/EFV) Versus Epivir/Ziagen/Agenerase/Norvir (3TC/ABC/APV/RTV) in HIV Patients Who Have Never Received Treatment

Phase 4

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2005-06-24

Lead Sponsor: Glaxo Wellcome

Target Recruit Count: 300

Registration Number: NCT00005017

Locations: 🇺🇸
Jaime Hernandez, Research Triangle Park, North Carolina, United States

A Study to Compare The Ability of Different Anti-HIV Drugs to Decrease Viral Load After Nelfinavir (an Anti-HIV Drug)Treatment Failure

Phase 2

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2012-05-21

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 300

Registration Number: NCT00000918

Locations: 🇺🇸
UCLA CARE Ctr, Los Angeles, California, United States
🇺🇸
Univ of Miami School of Medicine, Miami, Florida, United States
🇺🇸
Cook County Hosp, Chicago, Illinois, United States

and more 36 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy